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Abstract 
Three drugs with different hydrophilicity are encapsulated in poly-lactide (PLA) and 
Poly(lactide-co-glycolide) (PLGA) drug delivery systems prepared by ring-opening polymeri-
zation (ROP). Formation of well-defined core-shell type nanoparticles (NPs) is observed for 
α-tocopherol (TP) and by systematically altering the hydrophilicity of the drug carrier NPs the 
entrapment efficiency (EE (%)) can be remarkably controlled. The highest (90 %) of EE (%) 
is obtained for the most lipophilic TP from the applied three drugs in the 75 % lactide-
containing PLGA75 NPs, which is ca. 69 % for PLA NPs. Subsequent to drug loading the 
detailed characterization of the polymer and the NP formation was carried out. Precipitation 
titrations reveal that our PLGA have narrower weight distribution than the commercially 
available polymer enabling favourable properties to obtain NPs with better size distribution. It 
is pointed out that during the synthesis the applied solvent and stabilizing agent play a deci-
sive role in the size distribution and stability of the drug carrier NPs. The Pluronic F127-
stabilized NPs have the smallest diameter (ca. 190 nm) with less polydispersity among the 
applied stabilizing agent in nanoprecipitation.  
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1. Introduction 
The development of effective drug-delivery systems is a popular topic in todays’ 
pharmaceutical or nanomedicine-motivated research [1–3]. The micro- or nanoencapsulation 
of a pharmaceutical ingredients is a promising a widely used way of drug formulation 
technology enabling a number of interesting novel pharmaceutical delivery concepts. For 
instance, in controlled drug release applications, encapsulation enhances and prolongs the 
effectiveness of active ingredients, while in drug targeting, polymeric-based particles can be 
used as carriers for the targeted delivery of the drug to a specific site of action [4]. One class 
of the wide range of applied materials are the polymers like polystyrene (PS), N-
Isopropylacrylamide (NIPAM) and PLA/PLGA [5,6]. The excellent biocompatibility, low cost 
and good material properties of PLA would open many applications in the medical field, such 
as drug delivery systems [7–10]. Here we report the preparation technique and detailed 
characterization of the polymer properties and molar mass. There are several methods to 
prepare PLGA NPs including simple or w/o/w double emulsion method, salting-out etc. 
[11,12]. Nanoprecipitation excels due to its ease of processing and reproducibility and mainly 
applied for hydrophobic drugs [4].  
Three types of drugs as model molecules were tested in PLGA carriers like ketoprofen (KP), 
which is a non-steroidal anti-inflammatory drug (NSAID) mainly used in treatment of acute 
pain and chronic arthritis [13]. The more hydrophobic α-Tocopherol is an organic compound 
of vitamin E activity thus can be used in the prevention and treatment of some chronic, age-
related diseases [14]. A water-soluble derivative of TP, D-α-Tocopherol polyethylene glycol 
1000 succinate (TPGS) was also applied. Vitamin E evolves its activity as a chain-breaking 
antioxidant that stops the free radical reactions [15]. Moreover, encapsulated vitamin E is 
more effective against oxidation as compared to free vitamin E [16]. Several publications 
concentrate on the release properties of prepared or purchased PLGA NPs, however, very few 
describes the polymer properties and their effect on the forming NPs and their EE (%) 
[17,18]. Our results point out that by choosing the appropriate polymer, PLA or PLGA co-
polymers having 65% (PLGA65) and 75% (PLGA75%) lactide monomer content, the EE (%) 
can be significantly enhanced, moreover, at given concentration the TP drug can be enclosed 
in the polymer shell providing further favorable properties in release. 
 
2. Experimental section 
2.1. Materials 
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Lactide (3,6-Dimethyl-1,4-dioxane-2,5-dione) and glycolide (1,4-dioxane-2,5-dione) 
purchased from Sigma-Aldrich and Tin(II) 2-ethylhexanoate (from Alfa Aesar) and 1-
dodecanol (from Fluka) were used in the polymer synthesis. PLGA having different lactide : 
glycolide component ratio (PLGA65, 65:35, MW = 66.000 – 107.000 and PLGA75, 75:25, 
MW = 40.000 – 75.000, from Sigma–Aldrich) and PLA (MW = 250.000, from Fluka) were 
used as reference in this study. polyvinyl alcohol (PVA) (MW = 72000), Pluronic F127, 
hexadecyltrimethylammonium bromide (CTAB), ketoprofen (KP), D-α-tocopherol 
polyethylene glycol 1000 succinate (TPGS), and (±)-α-tocopherol (TP) was obtained from 
Sigma–Aldrich. Water was purified with a Millipore purification apparatus (18.2 MΩ·cm). 
2.2. Synthesis of PLGA copolymers 
The PLGA/PLA co-polymers with varied hydrophilicity were synthesized by ring-opening 
polymerization (ROP) [9,19,20]. The D,L–lactide (PLA: 5.0015 g, PLGA75: 3.7520 g, 
PLGA65: 3.2513 g) and glycolide (PLA: 0 g, PLGA75: 1.2510 g, PLGA65: 1.7502 g) were 
put into a round-bottomed flask with 0.02 % tin-octanoate catalyst (of the total dimers mass) 
and 0.01 % 1-dodecanol initiator. The tin-octanoate catalyzed the polycondensation reaction 
[10,21], while the 1-dodecanol functioned as initiator and has double role, it activates the 
catalyst on the other hand as a nucleophile agent takes part in the ring-opening step. After the 
components were added, the system was closed and placed under vacuum in order to remove 
the water molecules. To initiate the polycondensation reaction, the flask was placed in a 
preheated oil bath at 170-180 °C. In favor of better homogenization, magnetic stirring was 
used during the synthesis. After two hours the products was poured into a sealed flask in a 
refrigerator at -20 °C. The Vacuum, high temperature and magnetic stirring were crucial 
factors of the prosperous synthesis.  
It is important to note, that the initiator and the catalyst have low toxicity [9,22]. Both 
components are used in the food, pharmaceuticals and cosmetics industries. Thanks to the low 
toxicity and concentration the presence of the tin-octanoate and 1-dodecanol were not 
signified problem.  
2.3. Synthesis of PLGA/PLA NPs 
PLGA/PLA NPs were prepared by nanoprecipitation method [10,12,19,21,23–25]. In the first 
step the synthetized PLGA/PLA (15 mg) was dissolved in the organic phase (acetone or 1,4-
dioxane) (1.5 mL) and the applied stabilizers (such as CTAB, Pluronic F127 or PVA) (1.5 mg) 
in the aqueous phase (15 mL). Depending on their hydrophilicity, the drug (7.5 mg) was 
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added to the aqueous (TPGS) or the organic phase (KP, TP). Then the organic phase was 
added dropwise (10 μL) to the aqueous phase under continuous magnetically stirring (1000 
rpm) at room temperature. The obtained NP dispersions were stirred (350 rpm) for two days. 
Due to its higher boiling temperature the 1,4-dioxane not evaporated completely, but in the 
course of additional cleaning steps it got away. The prepared dispersions were added to 40 mL 
MQ water and centrifugated at 12000 rpm (t = 15 min, T = 25 °C). The NPs was retrieved by 
redispersation in 40 mL MQ water. The washing steps were repeated two times. The purified 
NP dispersion was lyophilized. 
2.4. Polymer characterization methods 
The DSC curves were recorded by Mettler Toledo DSC822
e
. In the test, the solid samples was 
heated from 25 °C to 425 °C, at rate of 5 °Cmin–1 in a sealed Aluminum sample holder with a 
hole at the top. Nitrogen was used as the carrier gas at a flow rate of 50 mLmin–1. As a 
reference, the monomers was measured too. Infrared spectra of the monomers and polymers 
were measured by Jasco FT/IR-4700 in the attenuated total reflectance (ATR) mode at room 
temperature from 3500 cm
–1
 to 700 cm
–1
. The resolution was 2 cm
-1
 with 256 scans for all the 
samples. 
The size and molecular weight of PLGA/PLA NPs were determined by Horiba SZ-100. In 
both cases, the test was performed at scattering angle of 90 °C and 25 °C temperature. The 
experimental error determined for the average particle size from the parallel measurement was 
below 2.5 %. For the measurements of the molecular weight, the PLGA/PLA polymers was 
dissolved in 1,4-dioxane. Molecular weight (MW) and second virial coefficient (A2) was 
identified by Rayleigh-Gans-Debye modell (Eq. 1). Toluene was used as the reference 
dispersion solvent to determine the extra Rayleigh ratio (Rex). The concentration dependence 
of refractive index of each sample were determined by Mettler Toledo RM50 refractometer 
which were important to count the optical constant (K). Value of the structure factor (P(θ)) 
was one for each cases. The C was the concentration of the polymer solutions in mg·mL–1. 
The prediction intervals of MW were determined from the linear fitting. 
  
   
  
 
       
       (1) 
The used solvents (MQ water, 1,4-dioxane) were filtered by 0.2 μm syringe filters 
(Hydrophobic PTFE 0.2 μm, for 1,4-dioxane and Nylon 0.2 μm for MQ water, Merck Kft., 
Germany Millipore Millex-FG, Merck Kft., Germany).  
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Precipitation titrations of PLGA co-polymers were carried out at 25 °C with initial solution 
concentrations of 5 mg·mL
-1
, 1,4-dioxane as good- solvent and water as poor- solvent or 
precipitant. The change in absorbance caused by the precipitation induced formation of 
polymer NPs, which was followed by UV-an Ocean Optics type USB4000 spectrophotometer 
in duplicate. For best palpability the absorbance percentage (A/Amax×100 at λ = 650 nm) were 
plotted in the function of the volume percentage of the water. The ratio of the amount of light 
absorption to the absorption at complete precipitation, i.e., complete precipitation corresponds 
to 100 % turbidity. Also, the volume per cent precipitant has been calculated as if the volumes 
of solvent and precipitant were strictly additive. The monomer composition adjusted 
hydrophilicity of the synthesized polymers was determined by contact angle measurements. A 
portion of polymers was melted on microscope glass slides at 160 – 170 °C in order to get 
smooth polymer film surface. The value of the water contact angle could be perfectly 
calculated with FM40Mk2 Easy Drop on the thus prepared surfaces at room temperature. The 
water drops were added with a syringe equipped with a 0.5 mm diameter steel needle. The 
volume of the drops was 10 μL in every measurements. For the sake of comparison the 
analysis was also performed with the purchased PLGA/PLA. 
2.5. Particle characterization methods 
The TEM images were obtained in a Jeol JEM-1400plus equipment (Japan) at 120 keV 
accelerating voltage. The SEM measurements were performed by a field emission scanning 
electron microscope (FESEM, Hitachi S-4700) applying a secondary electron detector and 5 
kV acceleration voltage. 
For the determination of EE (%) in w/w % the hydrophobic drug-loaded PLGA/PLA NPs 
were dissolved in 1,4-dioxane and the concentration of the released drug were determined 
from the previously measured calibration curves from 500 nm to 200 nm using UV-Vis 
spectrophotometer (Fig. S1, Fig. S2). The obtained data was divided by the total mass of 
drugs used in formulation (Eq. 2). 
 
    
                             
                                
      (2) 
 
For the TPGS containing PLGA/PLA NPs the EE (%) was determined indirectly (Fig. S3). 
The original dispersions (after the volume was set back to 15 mL) were centrifuged at 12000 
6 
rpm (t = 15 min) and the UV spectra of the supernatants were used to determine the mass of 
the drug in NPs (Eq. 3). 
 
    
                                 –                           
                                
      (3) 
3. Results and discussion 
3.1. Characterization of polymers 
The result of IR measurements confirmed the polymer formation. The peaks characteristic of 
the ester binds in the area denoted in Fig. 1A around 1750 cm
-1
 is for C=O bond, while the 
two at lower wavelengths (signed with blue and red lines in the online version) are for the C-
O ester bond. The latter is similar in case of the polymers, while different from the spectra of 
the dimers. The C=O stretching region appears in the IR spectra as a broad asymmetric band 
mainly due to A and E1 active modes especially for glycolide. The IR bands at 2997 and 2949 
cm
-1
 were assigned to the CH stretching region –CH3(asym), CH3(sym).. The FTIR spectrum of a 
polymer in the fingerprint region ( ≤ 1500 cm-1) is used to identify and characterize the 
material, since the observed peaks can be assigned to different vibration modes of chemical 
groups by comparison with cataloged FTIR spectra [10]. The CH3 is responsible for the 
appearance of the band at 1450 cm
-1
. The CH deformation and asymmetric bands appear at 
1382 cm
-1
. The C-O stretching modes of the ester group appear at 1211 cm
-1
 and the C-O-C 
asymmetric mode appears at 1130 cm
-1
. At 956 and 921 cm
-1
, we can find the bands 
characteristic of the helical backbone vibrations with the CH3 rocking modes. At 871 and 756 
cm
-1
, two bands appear that can be attributed to the amorphous and crystalline phases of PLA, 
respectively.  
 
Fig. 1 
 
DSC measurements were carried out to control either the polymerization was successful. The 
thermogravimetric curves of the polymers were compared to the initial dimers' (Fig. 1B). PLA 
is a semi-crystalline or amorphous polymer with a glass transition (Tg) and melting 
temperature (Tm) of approximately 55 °C and 180 °C, respectively. In our case the melting and 
glass transition temperature values are in accordance with the data found in literature [23]. 
The decomposition of the polymers took place at 304 °C for the pure PLA and systematically 
increases with decreasing lactide content to 341 °C for PLGA65. This is maybe due to the 
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higher intermolecular interactions among the hydrophilic parts of the macromolecular chains. 
Characteristic thermal data of the purchased PLGA/PLA were also determined for 
comparison. The results were similar to the synthesized PLGA/PLA (Table 1.). The thermal 
properties of the PLA can be varied by different parameters, mainly by the molecular weight 
and composition of D and L stereoisomers.  
Table 1. 
 
The molar mass-related properties are essential, because they influence the particle-related 
parameters such as the diameter and the polydispersity. Therefore the molar weights are 
represented in Table 1. For the purchased polymers are given as are presented in the 
compounds, while it was determined by DLS for the synthesized polymers. Based on the DLS 
results, the highest molar weight value was obtained for the less hydrophobic PLGA65 
polymer. This is probably due to the higher glycolide formation rate. Significantly lower 
values were obtained for the initial hydrophobic PLA and the partially hydrophilized PLGA75 
polymer (Fig. 2.) The change in the refractive index was similar for the PLGA75 and 65 
samples. Therefore the difference of the refractive indexes not influenced the DLS 
measurements either the molecular weight or the determination of the NP size. The value of 
the second virial coefficient corresponds to hydrophilicity of polymers, especially in case of 
PLGA65 and PLGA75. For PLA this value could be determined with higher error. 
 
Fig. 2. 
 
The further investigations were related to the verification of the successful modification of 
polymer hydrophilicity. During the contact angle measurements, both the purchased and 
prepared polymers, the water was dropped on the form of melted polymer film with smooth 
surface. The results and the photos taken from the water drops were presented in Fig. 3A. The 
contact angle decreased from 74.55° to 68.18 with decreasing amount of lactide part from 100 
% (PLA) to 65 % (PLGA65). It proved that the hydrophilicitiy systematically change with the 
lactide:glycolide ratio. In addition, the contact angle are within the margin of error for our 
synthesized samples and the so called original, purchased one, which is demonstrated in Fig. 
3A.  
Fig. 3 
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Further details can be obtained from the titration (e.g. solvent- change mediated precipitation) 
of polymer solution proceeding from good solvent (organic medium) with distilled water as 
poor solvent. According to the theory of Schulz, this fractional precipitation when we add 
non- solvent to a dilute polymer solution is also suitable for the determination of polymer 
molecular weight if the necessary constants are available [26]. Unfortunately, these constants 
were not found in the literature for our PLGA co-polymers and solvents, thus only the 
obtained precipitation curves can be presented without the corresponding molecular weights. 
The titration curve of our synthesized polymers were compared with the purchased ones, and 
the highest slope suggests tighter mass distribution in both co-polymers. The originally 
transparent solution became turbulent and polymer precipitation was observed without 
dissolving with mixing (Fig. 3B). Based on the curves we can state that our PLGA75 sample 
has smaller average mass than the purchased (Mw = 66-107 kDa), while our PLGA65 has 
higher (Mw = 40-70 kDa). The results are in accordance with the molecular weight obtained 
from light scattering. 
The turbidity of the polymer solution (i.e. the formation of polymer NPs in the solvent 
mixture) at the final state of the titration relative to the initially clear transparent solution also 
could be seen by naked eyes as the photos in Fig. 3B represents. This mechanism is also 
suitable for the encapsulation of (hydrophobic) drug particles into polymer shell [27].  
3.2. Characterization of polymeric NPs 
After the determination of polymer quality, we examined how the structure and the particle 
size of the PLGA/PLA NPs depend on the solvents (1,4 dioxane, acetone) and stabilizing 
agents (CTAB, PVA, Pluronic F127). The Fig 4. presents the characteristic forms of the 
PLGA/PLA NPs with the three different stabilizing agents applied. Low-magnification image 
for the samples with several particles can be inspected in the first line, while some particles 
for the same samples are magnified in the second line. CTAB surfactant as stabilizer resulted 
in the highest particles and particle-formation from the polymer was not complete. The NPs 
are sometimes attached to each other as oblivious for the Pluronic F127-stabilized one, though 
the PVA-stabilized seem less monodisperse relative to the Pluronic-stabilized NPs. 
Fig. 4 
 
The average particle diameter was determined both from TEM images and by DLS 
measurements. The Table 2. summarizes the average particle diameter of the prepared NPs by 
different methods and stabilizing agent. Hereby the effect of solvent, lactide to glycolide ratio 
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and stabilizing agents on the forming particle average diameter was investigated. It also can 
be seen, that the increasing GA content caused a decrease in the measured particles size in all 
cases.  
 
Table 2 
 
As for the polymer composition, the PLA-based NPs showed the highest diameter. Their 
hydrophobic nature resulted in precipitates with higher diameter. The particles were smaller in 
every cases when the acetone was used as organic solvent for the preparation of NPs. Based 
on this observation, the type of the organic solvent significantly influences the particle size. 
The DLS results also verify the higher particle size of NPs if stabilized with the CTAB.  The 
smallest particles were obtained for the Pluronic F127 stabilized systems, these were the basis 
of our further drug-carrier studies as the preferred size of NPs are in the 70-200 nm range for 
clinical application [28] due to the size of openings, also called fenestration of the endothelial 
barrier [29].  
For drug-containing NPs, the lyophilization of the samples is essential for further analysis and 
also for storing. The way and temperature of freezing followed by lyophilization is crucial to 
ensure the unchanging properties like particle size and dispersible properties. If the sample 
was frozen in an ultra-freeze drier at -60 °C, the temperature distribution was not uniform, the 
structure was destructed resulting in attached spheres, and the particles were not redispersible. 
If liquid nitrogen was used dropwise to refrigerate the NPs under mixing, due to the 
homogeneous freezing, the particles were less aggregated. The difference can be discovered in 
both SEM and TEM images (Fig. S4). 
3.3. Characterization of the drug-containing carrier systems 
In order to utilize the PLA/PLGA NPs in drug delivery, it is important to determine the effects 
of drugs with different hydrophilicity (TPGS, KP, TP) on the nanoparticles. First of all the 
diameters of the PLGA/PLA NPs were measured by DLS. The particle size distribution 
curves of a few sample with a photo presenting one of the samples can be seen in Fig. S5. The 
drug-free samples show the more monodisperse size distribution relative to the drug-
containing ones. The size enhancement due to the presence of drug is the most expressed in 
case of TP. The average particle diameter and encapsulation properties of different 
PLA/PLGA-drug systems are summarized in Table 3. 
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Table 3 
 
Similar particle sizes were obtained for the drug-free particles regardless of the polymer type. 
The encapsulation of the drug increased the particle size especially in the case of TP as the 
efficiency values imply. The hydrophobic drug can be enclosed most efficiently in the 
polymers in these types of PLGA NPs. Presumably the more hydrophobic nature of the 
polymer supports the trapping of TP inside the polymer matrix in the aqueous medium. The 
TEM images explain the more expressed particle size enhancement in case of TP. The images 
clearly shows the TP is encapsulated inside the polymer forming a core-shell like structure 
(Fig. 5). This entrapped form of TP is advantageous for several reasons like the release 
measurements, where we can controlled and thus the dose frequency can be reduced to the 
drugs. Furthermore, the bioactivity and stability of the active substance entrapped in the NPs 
is protected by encapsulation and also the bioavailability was shown to increase which is 
critical for lipophilic components such as vitamin E [30]. No characteristic difference can be 
observed if TPGS or KP is encapsulated, but for TP the difference is striking. 
Fig. 5 
 
Highest EE (%) was achieved for the most hydrophobic, TP drug. Core-shell type of 
encapsulation can be only achieved in our samples if the hydrophobic nature of the drug and 
the polymer is similar thus their precipitation coincide. In this case the drug is entrapped by 
the inner, more hydrophobic parts of the polymer during the nanoprecipitation. If the drug 
(like in case of KP and TPGS) is more hydrophilic than the polymer the precipitation of the 
drug is followed by the contraction of the polymer. The difference in KP and TPGS 
hydrophilicity is perfectly presented in the EE (%) values of PLA (Table 3), where almost 
double amount of KP is encapsulated relative to the TPGS, while there extent are similar for 
PLGA75 carrier. The EE (%) data also proves that the polymer structure affects the EE (%) as 
it can be increased from 6.4 to 11.3 for TPGS. Other parameters like drug concentration, drug 
to polymer ratio also effects the EE (%) while entrapment of the hydrophilic drugs can only 
be ensured if the drug is attached to the polymer chains, which has low probability in diluted 
polymer solution. Both KP and TPGS can be adsorbed on the surface of the nanoparticles as 
illustrated in the sketches in Fig. 5. 
The distinction between the two types of encapsulation is represented in the drawings 
illustrating each drug-containing NP. Some of the drug is presumably entrapped in the case of 
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KP or TPGS, not enough to form a continuous drug-phase inside the polymer chain-shell. 
Drug molecules adsorbed on the surface of NPs is probable for nanoprecipitation.  
 
 
4. Conclusion 
Both hydrophilic and hydrophobic drugs were encapsulated in PLA and PLGA co-polymers 
of different composition. Our polymers have favorable properties relative to the purchased 
ones, with slightly different average molar mass and narrower weight distribution. The surface 
wetting properties changed according to the composition as the contact angles decreased with 
decreasing lactide content of the co-polymer. The size of polymeric NPs can be tuned with the 
nanoprecipitation method in the 180-380 nm range by choosing of the adequate solvent or the 
stabilization agent. The CTAB as stabilizing agent resulted the highest average particle size 
and Pluronic F127 the smallest one in every case. The encapsulation efficiency for the most 
hydrophobic tocopherol is outstanding and was best for PLGA75 sample. High EE (%) 
(around 90 %) was also observed in PLA or PLGA polymers in other studies, but not in the 
TP-PLGA NPs [18,20,30]. Unlike TPGS and KP, the TP can be evolved the core-shell 
structure with PLGA/PLA. The key factor to obtain entrapped drug in the polymer is the 
simultaneous precipitation of the components. The EE (%) can be further enhanced by the 
appropriately chosen co-polymer composition and solution composition (drug concentration 
and drug to polymer ratio) as presented in this study. 
Acknowledgement 
The research was supported by the National Research, Development and Innovation Office-
NKFIH through the project K116323 and GINOP-2.3.2-15-2016-00060. V. H. acknowledges 
the Premium Post Doctorate Research Program of the Hungarian Academy of Sciences for the 
financial support. This paper was supported by the János Bolyai Research Scholarship of the 
Hungarian Academy of Sciences (E. Csapó). The Ministry of Human Capacities, Hungary 
grant 20391-3/2018/FEKUSTRAT is acknowledged. 
 
 
  
12 
References 
[1] J. Khandare, T. Minko, Polymer-drug conjugates: Progress in polymeric prodrugs, 
Prog. Polym. Sci. 31 (2006) 359–397.  
[2]  . .  u en,  .  uleta, A.M.  rean, A. . Moore, N.  gn atovic ,  .  skokovic , 
Improved percutaneous delivery of ketoprofen using combined application of 
nanocarriers and silicon microneedles, J. Pharm. Pharmacol. 65 (2013) 1451–1462.  
[3] A.I. Arida, M.M. Al-Tabakha, Encapsulation of ketoprofen for controlled drug release, 
Eur. J. Pharm. Biopharm. 66 (2007) 48–54.  
[4] J. Kluge, M. Mazzotti, G. Muhrer, Solubility of Ketoprofen in colloidal PLGA, Int. J. 
Pharm. 399 (2010) 163–172.  
[5] K. Molnár, C. Voniatis, D. Fehér, A. Ferencz, L. Fónyad, L. Reiniger, M. Zrínyi, G. 
Wéber, A. Jedlovszky-Hajdú, Biocompatibility study of poly(Vinyl alcohol)-based 
electrospun scaffold for hernia repair, Express Polym. Lett. 12 (2018) 676–687.  
[6] M. Mir, N. Ahmed, A. ur Rehman, Recent applications of PLGA based nanostructures 
in drug delivery, Colloids Surfaces B Biointerfaces. 159 (2017) 217–231.  
[7] S. Xie, S. Wang, L. Zhu, F. Wang, W. Zhou, The effect of glycolic acid monomer ratio 
on the emulsifying activity of PLGA in preparation of protein-loaded SLN, Colloids 
Surfaces B Biointerfaces. 74 (2009) 358–361.  
[8] R. Manchanda, A. Fernandez-Fernandez, A. Nagesetti, A.J. McGoron, Preparation and 
characterization of a polymeric (PLGA) nanoparticulate drug delivery system with 
simultaneous incorporation of chemotherapeutic and thermo-optical agents, Colloids 
Surfaces B Biointerfaces. 75 (2010) 260–267.  
[9] D. Bendix, Chemical synthesis of polylactide and its copolymers for medical 
applications, Polym. Degrad. Stab. 59 (1998) 129–135.  
[10] R. Auras, L-T. Lim, S.E.M. Selke, H. Tsuji, Poly(lactic acid) synthesis, structures, 
properties, processing and applications., Wiley, Hoboken NJ, USA, 2010, Chapter 6. 
 [11] R. Pahuja, K. Seth, A. Shukla, R.K. Shukla, P. Bhatnagar, L.K.S. Chauhan, P.N. 
Saxena, J. Arun, B.P. Chaudhari, D.K. Patel, S.P. Singh, R. Shukla, V.K. Khanna, P. 
Kumar, R.K. Chaturvedi, K.C. Gupta, Trans-blood brain barrier delivery of dopamine-
loaded nanoparticles reverses functional deficits in parkinsonian rats, ACS Nano. 9 
13 
(2015) 4850–4871. 
[12] J. Nicolas, S. Mura, D. Brambilla, N. MacKiewicz, P. Couvreur, Design, 
functionalization strategies and biomedical applications of targeted 
biodegradable/biocompatible polymer-based nanocarriers for drug delivery, Chem. Soc. 
Rev. 42 (2013) 1147–1235.  
[13] E. Csapó, H. Szokolai, Á. Juhász, N. Varga, L. Janovák, I. Dékány, Cross-linked and 
hydrophobized hyaluronic acid-based controlled drug release systems, Carbohydr. 
Polym. 195 (2018) 99–106.  
[14]  . . Zigoneanu,  .E. Astete,  .M.  abliov, Nanoparticles with entrapped α-tocopherol: 
Synthesis, characterization, and controlled release, Nanotechnology. 19 (2008) 105606.  
[15] C.E. Astete, D. Dolliver, M. Whaley, L. Khachatryan, C.M. Sabliov, Antioxidant 
poly(lactic-co-glycolic) acid nanoparticles made with  α-tocopherol-ascorbic acid 
surfactant, ACS Nano. 5 (2011) 9313–9325.  
[16] A. Murugeshu, C. Astete, C. Leonardi, T. Morgan, C.M. Sabliov, Chitosan/PLGA 
particles for controlled release of α-tocopherol in the GI tract via oral administration, 
Nanomedicine. 6 (2011) 1513–1528.  
[17] D. Ding, Q. Zhu, Recent advances of PLGA micro/nanoparticles for the delivery of 
biomacromolecular therapeutics, Mater. Sci. Eng. C. 92 (2018) 1041–1060.  
[18] S. Alqahtani, L. Simon, C.E. Astete, A. Alayoubi, P.W. Sylvester, S. Nazzal, Y. Shen, Z. 
Xu, A. Kaddoumi, C.M. Sabliov, Cellular uptake, antioxidant and antiproliferative 
activity of entrapped α-tocopherol and γ-tocotrienol in poly (lactic-co-glycolic) acid 
(PLGA) and chitosan covered PLGA nanoparticles (PLGA-Chi), J. Colloid Interface 
Sci. 445 (2015) 243–251.  
[19]  .  ’Avila  arvalho Erbetta, Synthesis and Characterization of Poly(D,L-Lactide-co-
Glycolide) Copolymer, J. Biomater. Nanobiotechnol. 03 (2012) 208–225.  
[20] A.T.C.R. Silva, B.C.O. Cardoso, M.E.S.R. e Silva, R.F.S. Freitas, R.G. Sousa, 
Synthesis, Characterization, and Study of PLGA Copolymer in vitro Degradation, J. 
Biomater. Nanobiotechnol. 06 (2015) 8–19.  
[21] M. Jamshidian, E.A. Tehrany, M. Imran, M. Jacquot, S. Desobry, Poly-Lactic Acid: 
Production, applications, nanocomposites, and release studies, Compr. Rev. Food Sci. 
14 
Food Saf. 9 (2010) 552–571. 
[22] K. Noweck, W.  rafahrend, Fatty Alcohols, in:  llmann’s Encycl. Ind. Chem., Wiley-
VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2006.  
[23] K. Hamad, M. Kaseem, H.W. Yang, F. Deri, Y.G. Ko, Properties and medical 
applications of polylactic acid: A review, Express Polym. Lett. 9 (2015) 435–455.  
[24] J.P. Rao, K.E. Geckeler, Polymer nanoparticles: Preparation techniques and size-
control parameters, Prog. Polym. Sci. 36 (2011) 887–913.  
[25] É. Kiss, G. Gyulai, C.B. Pénzes, M. Idei, K. Horváti, B. Bacsa, S. Bosze, Tuneable 
surface modification of PLGA nanoparticles carrying new antitubercular drug 
candidate, Colloids Surfaces A Physicochem. Eng. Asp. 458 (2014) 178–186.  
[26] A.R. Shultz, P.J. Flory, Phase Equilibria in Polymer—Solvent Systems, J. Am. Chem. 
Soc. 74 (1952) 4760–4767.  
[27] L. Janovák, Á. Turcsányi, É. Bozó, Á.  eák, L. Mérai,  .  ebők, Á. Juhász, E.  sapó, 
M.M. Abdelghafour, E. Farkas, I. Dékány, F. Bari, Preparation of novel tissue acidosis-
responsive chitosan drug nanoparticles: Characterization and in vitro release properties 
of Ca
2+
 channel blocker nimodipine drug molecules, Eur. J. Pharm. Sci. 123 (2018) 79–
88.  
[28] G. Storm, S.O. Belliot, T. Daemen, D.D. Lasic, Surface modification of nanoparticles 
to oppose uptake by the mononuclear phagocyte system, Adv. Drug Deliv. Rev. 17 
(1995) 31–48.  
[29] M. Gaumet, A. Vargas, R. Gurny, F. Delie, Nanoparticles for drug delivery: The need 
for precision in reporting particle size parameters, Eur. J. Pharm. Biopharm. 69 (2008) 
1–9.  
[30] K. Yokogawa, Y. Shima, T. Hashimoto, M. Hiyajyo, K. Kadoyama, J. Ishizaki, M. 
Nomura, K. . Miyamoto, High Bioavailabilty of α-Tocopherol Loaded into Poly (DL-
Lactic-co-Glycolic Acid) Microspheres in Apolipoprotein B Knockout Mice, Pharm. 
Res. 20 (2003) 1846–1850.  
 
  
15 
Figure and Table Captions 
Figure 1. (A) IR spectra and (B) DSC curves of prepared polymers and appropriate cyclic 
dimers 
Figure 2. (A) Molar weight and (B) refractive index determination of PLGA75 and PLGA65 
samples 
Figure 3. (A)Water contact angles on the surface of the synthesized and purchased polymers 
with different hydrophilicity and (B) Precipitation titration of PLGA co-polymers form 1,4-
dioxane solution with MQ water 
Figure 4. TEM representation of PLA NPs in the presence of different stabilizing agents 
Figure 5. TEM images of different drug-containing PLGA and PLA NPs and schematic, not 
scale representations of the location of drug in the carrier (inset) 
Table 1. DSC results (glass transition (Tg) and decomposition temperature (Td)), molecular 
weight (Mw) and the second virial coefficient (A2) of the synthesized and purchased 
PLGA/PLA determined by DLS 
Table 2. Polydispersity index (PI) and average hydrodynamic diameter of PLA and PLGA 
NPs prepared in different solvents determined by DLS 
Table 3. The average particle diameter determined by DLS and TEM, polidispersity index and 
encapsulation efficiency of Pluronic F127-stabilized drug-containing PLGA and PLA NPs 
Figures 
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Tables 
Table 1. 
 polymers Tg (C°) Td (C°) MW (Da) A2 (mL  mol/g
2
) 
sy
n
th
es
iz
ed
 
PLGA65 42 341 93000 ± 1000 6.15E-05 ± 5.17E-06 
PLGA75 45 317 69900 ± 4000 6.48E-04 ± 3.80E-05 
PLA 46 304 72200 ± 15000 2.70E-04 ± 3.29E-04 
p
u
rc
h
as
ed
 
PLGA65
#
 40 340 40000 – 75000 — 
PLGA75
#
 44 315 66000 – 104000 — 
PLA
#
 33 302 ≈ 250000 — 
# according to the material safety data sheets from Sigma-Aldrich 
 
 
  
 Table 2. 
 
polymer 
NPs 
CTAB PVA Pluronic F127 
PI dDLS ± SD
#
 
(nm) 
PI dDLS ± SD
#
 
(nm) 
PI dDLS ± SD
#
 
(nm) 
a
ce
to
n
e 
PLGA65 0.65 ± 0.05 228 ± 18 0.16 ± 0.07 211 ± 28 0.11 ± 0.07 186 ± 32 
PLGA75 0.47 ± 0.02 261 ± 16 0.06 ± 0.04 221 ± 63 0.10 ± 0.01 180 ± 33 
PLA 0.56 ± 0.10 355 ± 27 0.17 ± 0.03 243 ± 72 0.05 ± 0.05 190 ± 44 
1
,4
 d
io
x
a
n
e PLGA65 0.57 ± 0.08 239 ± 27 0.08 ± 0.03 260 ± 57 0.17 ± 0.04 232 ± 64 
PLGA75 0.48 ± 0.04 266 ± 23 0.09 ± 0.05 268 ± 51 0.09 ± 0.02 236 ± 53 
PLA 0.57 ± 0.03 381 ± 36 0.13 ± 0.06 271 ± 58 0.09 ± 0.04 260 ± 61 
#
the experimental error for the peak maximum is below 2.5 % 
 
  
Table 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#
the experimental error for the peak maximum is below 2.5 % 
 
polymer drugs PI dDLS ± SD
#
 
(nm) 
dTEM ± SD 
(nm) 
EE 
(%) 
P
L
G
A
6
5
 
— 0.11 ± 0.07 186 ± 32 164 ± 51 — 
TPGS 0.12 ± 0.03 178 ± 48 159 ± 63 11.34 
KP 0.14 ± 0.04 216 ± 62 204 ± 71 13.21 
TP 0.23 ± 0.03 253 ± 52 238 ± 59 88.25 
P
L
G
A
7
5
 
— 0.10 ± 0.01 180 ± 33 172 ± 49 — 
TPGS 0.07 ± 0.04 173 ± 47 160 ± 56 6.39 
KP 0.07 ± 0.01 207 ± 42 193 ± 69 7.91 
TP 0.19 ± 0.05 257 ± 75 238 ± 62 90.28 
P
L
A
 
— 0.05 ± 0.05 190 ± 36 183 ± 57 — 
TPGS 0.13 ± 0.05 195 ± 64 190 ± 76 6.88 
KP 0.09 ± 0.06 225 ± 48 211 ± 64 11.29 
TP 0.12 ± 0.05 257 ± 73 236 ± 77 69.07 
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 Diameter of the synthesized PLGA NPs depends on the organic solvents and stabilizer 
 DLS and turbidity results showed the synthesized PLGA had small average mass 
 Method of freeze-drying strongly influences the NPs size and redispersibility 
 Core-shell type of encapsulation can be obtained for tocopherol with 90% efficiency 
 
Highlights (for review)
